Literature DB >> 1632387

Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction.

T Sakamoto1, H Yasue, H Ogawa, I Misumi, T Masuda.   

Abstract

To examine the fibrinolytic capacity in patients with acute myocardial infarction (AMI), baseline levels of plasma plasminogen activator inhibitor (PAI) activity and tissue-type plasminogen activator (t-PA) antigen were measured in 47 patients with Q-wave AMI who underwent emergent coronary angiography 3.0 +/- 0.2 hours after the symptom onset. They received intracoronary injection of urokinase if their infarct-related arteries were occluded. They were classified into 3 groups according to the patency of the infarct-related artery before and after thrombolytic therapy: the patent group (13 patients), the recanalized group (23 patients) and the occluded group (11 patients). The mean level of plasma PAI activity (IU/ml) was higher in patients with AMI as a whole than in the control group (12.8 +/- 1.6 vs 5.4 +/- 0.5, p less than 0.01). The level was lower in the patent group (3.0 +/- 1.1) and higher in the recanalized (18.6 +/- 2.2) and occluded (10.8 +/- 2.5) groups than in the control group (each p less than 0.01). The level was lower in the occluded than in the recanalized group (p less than 0.01) and 62% of the patients in the occluded group had levels within range of the control group. The mean level of plasma t-PA antigen (ng/ml) was higher in patients with AMI as a whole than in the control group (10.3 +/- 0.8 vs 5.8 +/- 0.3, p less than 0.01). There was no difference in the level among the 3 groups with AMI.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632387     DOI: 10.1016/0002-9149(92)90603-v

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

2.  Circulating thrombotic and haemostatic components in patients with coronary artery disease.

Authors:  Kavita K Shalia; V K Shah; M R Mashru; S L Soneji; J B Vasvani; S S Payannavar; A P Walvalkar; R A Mokal; S M Mithbawkar; K V Kudalkar; A Abraham; P K Thakur
Journal:  Indian J Clin Biochem       Date:  2010-02-10

3.  Circadian variation in fibrinolytic activity in patients with variant angina.

Authors:  T Masuda; H Ogawa; Y Miyao; Q Yu; I Misumi; T Sakamoto; H Okubo; K Okumura; H Yasue
Journal:  Br Heart J       Date:  1994-02

4.  Experimental studies on preventive effects of API0134 on vessel reocclusion after thrombolysis.

Authors:  Y L Xiong; H Y Zhao
Journal:  J Tongji Med Univ       Date:  1995

5.  An In Silico Approach towards the Prediction of Druglikeness Properties of Inhibitors of Plasminogen Activator Inhibitor1.

Authors:  Umadevi Subramanian; Ashok Sivapunniyam; Ayyasamy Pudukadu Munusamy; Rajakumar Sundaram
Journal:  Adv Bioinformatics       Date:  2014-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.